• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Wilex AG - Product Pipeline Review - H2 2011 Product Image

Wilex AG - Product Pipeline Review - H2 2011

  • ID: 1964482
  • November 2011
  • 87 pages
  • Global Markets Direct

Wilex AG – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Wilex AG - Product Pipeline Review - H2 2011” provides data on the Wilex AG’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Wilex AG’s corporate website, SEC filings, investor presentations and featured press releases, both from Wilex AG and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Wilex AG - Brief Wilex AG overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Wilex AG human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product READ MORE >



List of Tables
List of Figures
Wilex AG Snapshot
Wilex AG Overview
Key Information
Key Facts
Wilex AG – Research and Development Overview
Key Therapeutic Areas
Wilex AG – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Wilex AG – Pipeline Products Glance
Wilex AG – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Wilex AG Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Wilex AG–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Wilex AG – Drug Profiles
Antibody 1
Product Description
Mechanism of Action
R&D Progress
Antibody-Drug Conjugate
Product Description
Mechanism of Action
R&D Progress
MESUPRON + Gemzar
Product Description
Mechanism of Action
R&D Progress
MESUPRON + Xeloda
Product Description
Mechanism of Action
R&D Progress
Rencarex
Product Description
Mechanism of Action
R&D Progress
WX-037
Product Description
Mechanism of Action
R&D Progress
WX-554
Product Description
Mechanism of Action
R&D Progress
WX-UK1
Product Description
Mechanism of Action
R&D Progress
WX-UK1 + Xeloda
Product Description
Mechanism of Action
R&D Progress
Wilex AG – Pipeline Analysis
Wilex AG – Pipeline Products by Therapeutic Class
Wilex AG - Pipeline Products By Target
Wilex AG – Pipeline Products by Route of Administration
Wilex AG – Pipeline Products by Molecule Type
Wilex AG – Recent Pipeline Updates
Wilex AG - Dormant Projects
Wilex AG – Company Statement
Wilex AG – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Sep 29, 2009: Mesupron In Combination With Gemcitabine Shows Clear Improvement In Tumour Response As Well As Median Survival And One Year Survival
Jan 28, 2008: WILEX Receives US FDA Aproval (IND) For Clinical Phase II Trial With Its uPA Inhibitor WX-671 In Metastatic Breast Cancer
Jul 27, 2005: Wilex Successfully Completes First Clinical Phase I Study With New Anti-Cancer Drug WX-671
Jun 26, 2007: Patient Recruitment Started In Clinical Phase II Trial With WX-671 In Pancreatic Cancer
Apr 26, 2004: Wilex And Esteve Sign Co-Development And Marketing Agreement For Rencarex In Southern Europe
Jan 25, 2008: WILEX AG completes Phase I study with uPA inhibitor WX-UK1
Sep 24, 2007: Phase Ib Trial With WX-671 In Patients With Head & Neck Cancer Successfully Completed
Jul 24, 2008: Patient Recruitment In Phase II Trial With Mesupron (WX-671) In Pancreatic Cancer Patients Successfully Completed
Jul 24, 2008: Wilex AG Successfully Completes Patient Recruitment In Phase II Trial With Mesupron (WX-671) In Pancreatic Cancer Patients
Jan 24, 2011: WILEX Announces Start Of Interim Analysis For Phase III ARISER Registration Trial With RENCAREX
Sep 20, 2004: Wilex Starts Clinical Trial With New Anti-Cancer Compound WX-671
May 19, 2005: Wilex’s Anti-Cancer Drug Rencarex Significantly Prolongs Survival In Metastatic Renal Cell Cancer
Dec 18, 2007: Wilex Updates The Status Of The Rencarex Phase III-ARISER Study
May 18, 2010: WILEX Announces Final Results From Phase III Trial Of REDECTANE
Jun 17, 2011: WILEX And IBA Report On Pre-BLA Meeting With FDA And Next Steps In REDECTANE Approval Process
Oct 16, 2006: Wilex Successfully Completes Phase II Study With Rencarex In Combination With Interferon
Dec 15, 2006: WILEX Receives Approval For Clinical Phase II Trial With Oral WX-671 and Gemcitabine In Pancreatic Cancer
Dec 15, 2006: WILEX Receives Approval For Clinical Phase II Trial With Oral WX-671 In Pancreatic Cancer
Sep 15, 2011: WILEX Starts First Oral Phase I Study With MEK inhibitor WX-554
Jun 15, 2004: Wilex Starts Patient Enrollment In Rencarex Pivotal Phase III Trial In Renal Cell Carcinoma
Dec 13, 2007: Wilex Announces Positive Result Of The Interim Analysis For Futility Of Its Phase III ARISER Trial With RENCAREX
Aug 11, 2008: Wilex Starts Patient Recruitment In Phase II Breast Cancer Trial With Its uPA Inhibitor Mesupron (WX-671)
May 10, 2004: Wilex Receives IND Approval From FDA For Phase III Trial With Rencarex In Renal Cell Carcinoma
Apr 09, 2002: Wilex’ s WX-G250 Renal Cancer Therapeutic Shows Clinical Benefit In Phase II Trial Interim PhaseI/II Data For WX-G250 + IL-2 Presented At AACR Annual Meeting
Jan 09, 2009: UCB And WILEX Enter Into Strategic Alliance To Develop UCB's Preclinical Oncology Portfolio
Jan 09, 2009: UCB And WILEX Enter Into Strategic Alliance To Develop UCB's Preclinical Oncology Portfolio
Oct 08, 2004: Wilex Acquires Option For US Marketing Rights To Rencarex
Apr 08, 2002: Wilex Receives Orphan Drug Designation In Europe For WX-G250
Aug 07, 2006: WILEX Completes Phase I Program With Anti-Cancer Drug WX-671 In Healthy Volunteers And Conducts Clinical Phase Ib Study In Cancer Patients Now
Jun 07, 2010: WILEX Presents Positive Final Phase II Data Of Mesupron At ASCO For The Treatment Of Pancreatic Cancer
Oct 05, 2011: FDA Grants Fast Track Designation To WILEX’s RENCAREX For Adjuvant Therapy Of Clear Cell Renal Cell Carcinoma
May 05, 2011: WILEX Completes Patient Recruitment In Phase II Breast Cancer Trial With MESUPRON
Aug 04, 2009: WILEX Files Application For Approval Of Phase I Trial For WX-554 And Thereby Achieves First Milestone Of The Strategic Aalliance With UCB
Jul 03, 2008: Phase III ARISER Study With Rencarex Completes Patient Recruitment
May 03, 2010: Final Phase II Data Of WILEX's MESUPRON Confirm Impressive Increase In Overall Survival Of Patients With Pancreatic Cancer
May 03, 2010: Wilex AG Announces Final Phase II Data Of Mesupron, Confirming Impressive Increase In Overall Survival Of Patients With Pancreatic Cancer
Apr 03, 2007: Wilex Gives Positive Update Of Current Pivotal Phase III Trial Of Rencarex
Oct 02, 2009: WILEX Receives Approval For Phase I Trial With MEK Inhibitor WX-554
Jun 01, 2001: Wilex Cancer Drug Receives Orphan Drug Designation
Mar 01, 2006: Wilex Appoints Members To Its Medical Advisory Board For Rencarex And The Phase III ARISER Study
Mar 01, 2004: Wilex’ Antibody Rencarex Shows Positive Long Term Survival In Follow-Up Of Phase II Trial In Renal Cell Carcinoma Patients
Financial Deals Landscape
Wilex AG, Deals Summary
Wilex AG, Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
WILEX To Acquire Oncogene Science Assets From Siemens Healthcare Diagnostics
Wilex Acquires Intellectual Property From Dendreon
Venture Financing
Wilex Secures $39 Million In Series C Financing Round
Heidelberg Pharma Secures $31 Million In The Second Round Of Venture Financing
Partnerships
WILEX Enters Into Licensing Agreement With Ion Beam Applications
WILEX Enters Into An Agreement With IBA Molecular
Wilex Enters Into Co-Development Agreement With Esteve
Licensing Agreements
WILEX Enters Into Licensing Agreement With Prometheus Laboratories For RENCAREX
UCB Enters Into Licensing Agreement With WILEX
Equity Offering
WILEX Enters Into Standby Equity Distribution Agreement For $27 Million
WILEX Completes Initial Public Offering Of $80 Million
Acquisition
WILEX To Acquire Heidelberg Pharma
dievini Hopp BioTech Holding Acquires 0.12% Stake In WILEX
UCB Pharma Acquires An Additional 6.65% Stake In WILEX
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Wilex AG – Pipeline by Therapy Area and Indication, H2 2011
Wilex AG – Pipeline by Stage of Development, H2 2011
Wilex AG – Monotherapy Products in Pipeline, H2 2011
Wilex AG – Combination Treatment Modalities in Pipeline, H2 2011
Wilex AG – Phase III, H2 2011
Wilex AG - Phase II, H2 2011
Wilex AG - Phase I, H2 2011
Wilex AG - Pipeline By Therapeutic Class, H2 2011
Wilex AG - Pipeline By Target, H2 2011
Wilex AG – Pipeline By Route of Administration, H2 2011
Wilex AG – Pipeline By Molecule Type, H2 2011
Wilex AG – Recent Pipeline Updates, H2 2011
Wilex AG - Dormant Developmental Projects, H2 2011
Wilex AG, Other Locations, H2 2011
Wilex AG, Subsidiaries, H2 2011
Wilex AG, Deals Summary, H2 2011
WILEX To Acquire Oncogene Science Assets From Siemens Healthcare Diagnostics
Wilex Acquires Intellectual Property From Dendreon
Wilex Secures $39 Million In Series C Financing Round
Heidelberg Pharma Secures $31 Million In The Second Round Of Venture Financing
WILEX Enters Into Licensing Agreement With Ion Beam Applications
WILEX Enters Into An Agreement With IBA Molecular
Wilex Enters Into Co-Development Agreement With Esteve
WILEX Enters Into Licensing Agreement With Prometheus Laboratories For RENCAREX
UCB Enters Into Licensing Agreement With WILEX
WILEX Enters Into Standby Equity Distribution Agreement For $27 Million
WILEX Completes Initial Public Offering Of $80 Million
WILEX To Acquire Heidelberg Pharma
dievini Hopp BioTech Holding Acquires 0.12% Stake In WILEX
UCB Pharma Acquires An Additional 6.65% Stake In WILEX

List of Figures
Wilex AG – Pipeline by Therapy Area and Indication, H2 2011
Wilex AG – Pipeline by Stage of Development, H2 2011
Wilex AG – Monotherapy Products in Pipeline, H2 2011
Wilex AG – Combination Treatment Modalities in Pipeline, H2 2011
Wilex AG – Pipeline By Therapeutic Class, H2 2011
Wilex AG - Pipeline By Target, H2 2011
Wilex AG – Pipeline By Route of Administration, H2 2011
Wilex AG – Pipeline By Molecule Type, H2 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos